Loading...
XNAS:SHPH
Shuttle Pharmaceuticals shares are trading lower after announcing a proposed 25-for-1 reverse stock split as part of a Nasdaq compliance strategy.
Shuttle Pharma shares are trading higher after the company announced it is nearly halfway through patient enrollment for its Phase 2 clinical trial of Ropidoxuridine, a treatment for glioblastoma, following an expedited trial progress and promising preliminary results.